JP2008546803A - 治療用ペプチドおよびワクチン - Google Patents

治療用ペプチドおよびワクチン Download PDF

Info

Publication number
JP2008546803A
JP2008546803A JP2008518460A JP2008518460A JP2008546803A JP 2008546803 A JP2008546803 A JP 2008546803A JP 2008518460 A JP2008518460 A JP 2008518460A JP 2008518460 A JP2008518460 A JP 2008518460A JP 2008546803 A JP2008546803 A JP 2008546803A
Authority
JP
Japan
Prior art keywords
composition
peptide
group
hiv
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008518460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546803A5 (https=
Inventor
パート，キャンディス
ラフ，マイケル
Original Assignee
ラピッド・ファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラピッド・ファーマシューティカルズ・インコーポレーテッド filed Critical ラピッド・ファーマシューティカルズ・インコーポレーテッド
Publication of JP2008546803A publication Critical patent/JP2008546803A/ja
Publication of JP2008546803A5 publication Critical patent/JP2008546803A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2008518460A 2005-06-23 2006-06-23 治療用ペプチドおよびワクチン Pending JP2008546803A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69308805P 2005-06-23 2005-06-23
US69308905P 2005-06-23 2005-06-23
US69308705P 2005-06-23 2005-06-23
PCT/US2006/024580 WO2006138745A2 (en) 2005-06-23 2006-06-23 Therapeutic peptides and vaccines

Publications (2)

Publication Number Publication Date
JP2008546803A true JP2008546803A (ja) 2008-12-25
JP2008546803A5 JP2008546803A5 (https=) 2012-03-15

Family

ID=37571305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008518460A Pending JP2008546803A (ja) 2005-06-23 2006-06-23 治療用ペプチドおよびワクチン

Country Status (9)

Country Link
US (3) US7700115B2 (https=)
EP (1) EP1893233A4 (https=)
JP (1) JP2008546803A (https=)
KR (1) KR20080019720A (https=)
AU (1) AU2006261133B2 (https=)
BR (1) BRPI0611927A2 (https=)
CA (1) CA2624957A1 (https=)
MX (1) MX2007016573A (https=)
WO (1) WO2006138745A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006261133B2 (en) 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines
US8178497B2 (en) 2007-11-14 2012-05-15 Rapid Pharmaceuticals Ag Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA
US10130674B2 (en) * 2010-02-09 2018-11-20 Creative Bio-Peptides Modified peptide that reduces pain in peripheral neuropathy
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
US20140322251A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions
US20180344798A1 (en) * 2017-05-31 2018-12-06 Creative Bio-Peptides Inc. Topically active peptides for treating cosmetic and dermatological conditions
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
US20210244788A1 (en) * 2020-02-06 2021-08-12 Creative Bio-Peptides Inc. Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501716A (ja) * 1985-10-24 1988-07-14 サウスウエスト・ファウンデ−ション・フォア・バイオメディカル・リサ−チ 合成ペプチドおよびａｉｄｓおよびａｒｃの診断ならびにワクチン注射へのその使用
JPH01502659A (ja) * 1986-06-03 1989-09-14 アメリカ合衆国 Ｔ−４レセプターへの結合を阻害し免疫原として作用する小ペプチド類

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007614A1 (en) * 1986-06-03 1987-12-17 Pert Candace B Small peptides which inhibit binding to t-4 receptors
US5276016A (en) * 1986-06-03 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Small peptides which inhibit binding to T-4 receptors and act as immunogens
US6242564B1 (en) 1986-06-03 2001-06-05 Candace B. Pert Treatment of tropical spastic paresis with peptide T
US5063206A (en) 1988-12-16 1991-11-05 The United States Of Americas As Represented By The Department Of Health And Human Services Compositions having use as treatment of neuropsychiatric deficits
US5739109A (en) 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
DK64592D0 (da) 1992-05-14 1992-05-14 Carlbiotech Ltd As Peptider til terapeutisk behandling
US6011014A (en) 1992-03-27 2000-01-04 Advanced Immunit, Inc. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US5534495A (en) 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US20040126811A1 (en) * 2002-02-21 2004-07-01 Thomas Boren Helicobacter pylori sialic acid binding adhesin, saba and saba-gene
US7390788B2 (en) 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
AU2006261133B2 (en) 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501716A (ja) * 1985-10-24 1988-07-14 サウスウエスト・ファウンデ−ション・フォア・バイオメディカル・リサ−チ 合成ペプチドおよびａｉｄｓおよびａｒｃの診断ならびにワクチン注射へのその使用
JPH01502659A (ja) * 1986-06-03 1989-09-14 アメリカ合衆国 Ｔ−４レセプターへの結合を阻害し免疫原として作用する小ペプチド類

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6011037082; Ｐｒｏｃｅｅｄｉｎｇｓ　ｏｆ　ｔｈｅ　Ｎａｔｉｏｎａｌ　Ａｃａｄｅｍｙ　ｏｆ　Ｓｃｉｅｎｃｅｓ　ｏｆ　ｔｈｅ　Ｕｎｉｔｅｄ　Ｓｔａｔｅｓ　ｏｆ　Ａｍｅｒｉｃａ Ｖｏｌ．８３，　Ｎｏ．２３, 1986, ｐ．９２５４-９２５８ *

Also Published As

Publication number Publication date
US20100184705A1 (en) 2010-07-22
EP1893233A2 (en) 2008-03-05
EP1893233A4 (en) 2010-03-31
CA2624957A1 (en) 2006-12-28
US10973906B2 (en) 2021-04-13
AU2006261133A1 (en) 2006-12-28
AU2006261133B2 (en) 2012-04-05
KR20080019720A (ko) 2008-03-04
BRPI0611927A2 (pt) 2011-08-16
US10071153B2 (en) 2018-09-11
MX2007016573A (es) 2008-10-17
US7700115B2 (en) 2010-04-20
US20060292167A1 (en) 2006-12-28
WO2006138745A2 (en) 2006-12-28
US20190000964A1 (en) 2019-01-03
WO2006138745A3 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
US10973906B2 (en) Therapeutic peptides and vaccines
Liu et al. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds
DE3855947T2 (de) Peptide mit den immunologischen Eigenschaften von HIV-2
US6335017B1 (en) Compositions and methods for treating viral infections
JP3369246B2 (ja) 遺伝的に分岐したｈｉｖ−１分離株を中和する抗体誘導能を有するペプチド
DE69133242T2 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
Fiorentini et al. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17
RU2432356C2 (ru) НОВЫЕ Tat-КОМПЛЕКСЫ И ВКЛЮЧАЮЩИЕ ИХ ВАКЦИНЫ
IE61966B1 (en) Protective peptides derived from human immunodeficiency virus-1 gp160
Kim et al. Enhancing HIV-1 neutralization by increasing the local concentration of membrane-proximal external region-directed broadly neutralizing antibodies
Giannecchini et al. Antibodies generated in cats by a lipopeptide reproducing the membrane-proximal external region of the feline immunodeficiency virus transmembrane enhance virus infectivity
Rey-Cuillé et al. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41
CN101242854A (zh) 治疗肽及疫苗
AU2006200454B2 (en) Compositions and methods for treating viral infections
WO2007020243A2 (de) Impfstoff auf basis virusneutralisierender antikörper
US10660951B2 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP1757304A1 (en) Pharmaceutical composition and its use for the prophylactic or therapeutic treatment of retroviral diseases
CN119837997A (zh) Tnfr2在制备治疗hiv感染的药物中的应用
US20070003565A1 (en) Use of hab18g/cd147 molecule as target for antiviral antagonists and thus obtained antiviral antagonist
JPH0748276A (ja) Ｈｉｖ感染症予防ワクチンおよびその製造法
CA2111681A1 (en) Mimic peptides of gp120
AU2004201322A1 (en) Compositions and methods for treating viral infections

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120116

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130902